Silexion Therapeutics (NASDAQ:SLXN) Price Target Cut to $5.00 by Analysts at Maxim Group

Silexion Therapeutics (NASDAQ:SLXN) had its price objective decreased by Maxim Group from $9.00 to $5.00 in a research report sent to investors on Thursday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Silexion Therapeutics Trading Up 2.7 %

NASDAQ:SLXN opened at $1.14 on Thursday. Silexion Therapeutics has a 1-year low of $0.58 and a 1-year high of $41.85. The stock has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $2.89.

Hedge Funds Weigh In On Silexion Therapeutics

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Wildcat Capital Management LLC purchased a new stake in Silexion Therapeutics Corp (NASDAQ:SLXN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,020,852 shares of the company’s stock, valued at approximately $536,000. Silexion Therapeutics accounts for approximately 0.3% of Wildcat Capital Management LLC’s investment portfolio, making the stock its 7th biggest position. Wildcat Capital Management LLC owned 7.38% of Silexion Therapeutics as of its most recent filing with the Securities and Exchange Commission. 10.95% of the stock is currently owned by hedge funds and other institutional investors.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.